DIM — Sartorius Stedim Biotech SA Balance Sheet
0.000.00%
- €19.71bn
- €21.97bn
- €2.78bn
Annual balance sheet for Sartorius Stedim Biotech SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 70.6 | 237 | 133 | 133 | 691 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 263 | 371 | 419 | 334 | 300 |
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 874 | 1,456 | 1,671 | 1,415 | 1,741 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 644 | 928 | 1,292 | 1,633 | 1,885 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 2,857 | 3,951 | 5,065 | 7,730 | 8,256 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 568 | 1,037 | 1,036 | 937 | 939 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 1,419 | 2,295 | 2,616 | 5,092 | 4,270 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 1,438 | 1,656 | 2,449 | 2,639 | 3,987 |
| Total Liabilities & Shareholders' Equity | 2,857 | 3,951 | 5,065 | 7,730 | 8,256 |
| Total Common Shares Outstanding |